Expertise article

Guilty Gilt Guide
Expertise article

Guilty Guilt Guide

The Guilty Gilt Guide was written with a clear objective – to maximize the whole-herd performance of pig populations by helping gilts to reach their full reproductive potential and produce healthy pigs that reach their full genetic potential during grow-finish.

prrs-Implementing
Expertise article

Implementing a user-friendly format to analyze PRRSV next-generation sequencing results and associating breeding herd production performance with number of PRRSV strains and recombination events

  • Expertise article
  • Giovani Trevisan, Michael Zeller, Ganwu Li, Jianqiang Zhang, Phillip Gauger, Daniel C.L. Linhares

The open reading frames (ORF)5 represents approximately 4% of the porcine repro- ductive and respiratory syndrome virus (PRRSV)-2 genome (whole-PRRSV) and is often determined by the Sanger technique, which rarely detects >1 PRRSV strain if present in the sample.

15-image-prrs
Expertise article

Refining PRRSV-2 genetic classification based on global ORF5 sequences and investigation of their geographic distributions and temporal changes

Porcine reproductive and respiratory syndrome virus (PRRSV) is an important swine pathogen affecting the global swine industry.

33-image-prrs
Expertise article

Effect of multiple vaccinations on transmission and degree of Mycoplasma hyopneumoniae infection in gilts

Mycoplasma hyopneumoniae (M. hyopneumoniae) infections continue to result in significant respiratory challenges in the swine industry worldwide. Vaccination for M. hyopneumoniae is commonly utilized, as reduction in bacterial loads and clinical severity in vaccinated pigs have been shown. However, the effect of M. hyopneumoniae vaccination on transmission across different pig populations has been minimally investigated.

img-13
Expertise article

Cell-mediated immune response and protective efficacy of porcine reproductive and respiratory syndrome virus modified-live vaccines against co-challenge with PRRSV-1 and PRRSV-2

Cell-mediated immunity (CMI), IL-10, and the protective efficacy of modified-live porcine reproductive and respiratory syndrome virus (PRRSV) vaccines (MLV) against co-challenge with PRRSV-1 and PRRSV-2 (HP-PRRSV) were investigated.

img-12
Expertise article

Commercial porcine reproductive and respiratory syndrome virus (PRRSV)-2 modified live virus vaccine against heterologous single and dual Korean PRRSV-1 and PRRSV-2 challenge

This study evaluated porcine reproductive and respiratory syndrome virus (PRRSV)-2 modiied live virus (MLV) vaccine against heterologous single and dual challenge of Korean PRRSV-1 and PRRSV-2. 

Image Error
Expertise article

Evaluation of a 20 year old porcine reproductive and respiratory syndrome (PRRS) modified live vaccine (Ingelvac1 PRRS MLV) against two recent type 2 PRRS virus isolates in South Korea

Type 2 porcine reproductive and respiratory syndrome (PRRS) virus (PRRSV) was first isolated in Korea in 1994. The commercial PRRS modified live vaccine (Ingelvac1 PRRS MLV, Boehringer Ingelheim Vetmedica Inc., St. Joseph, Missouri, USA) based on type 2 PRRSV, was first licensed for use in 3- to 18-week-old pigs in Korea in 1996.

img-11
Expertise article

Examination of viraemia and clinical signs after challenge with a heterologous PRRSV strain in PRRS Type 2 MLV vaccinated pigs: A challenge-dose study

Vaccination with porcine reproductive and respiratory syndrome (PRRS) Type 2 modified- live vaccines (MLVs) has been shown to improve clinical signs and survival rates in PRRS virus (PRRSV)-challenged pigs.